Market research
REPH Recro Pharma Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 123M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.12
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- ISIN
- US75629F1093
- Market cap
- 123M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.12
About
About Recro Pharma Inc
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the REPH discussion.
5 years, 4 months ago
Recro Pharma, Inc is currently in a long term downtrend where the price is trading 29.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Recro Pharma, Inc's total revenue sank by 43.8% to $10M since the same quarter in the previous year.
Its net income has dropped by 22.7% to $-12M since the same quarter in the previous year.
Finally, its free cash flow grew by 118.2% to $687K since the same quarter in the previous year.
Based on the above factors, Recro Pharma, Inc gets an overall score of 2/5.